Selvigaltin (GB1211), an orally obtainable small molecule galectin-three inhibitor developed being a therapy for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to address regulatory necessities. Desk 4 Statistical assessment of dose proportionality of the pharmacokinetic parameters of GB1211 pursuing https://hectormbmxi.blogdun.com/39939011/top-selvigaltin-galectin-3-inhibitor-secrets